Peptide · Research peptide

CJC-1295

Research peptide

Aliases · Modified GRF (1-29) · DAC-GRF · CJC1295 · CJC-1295 DAC · CJC-1295 with DAC · CJC 1295

CJC-1295 is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials.

Human

2/5

Animal

0/5

In-vitro

0/5

Safety

2/5

Last reviewed · 7/12/2026

Compare with another peptide →

Last reviewed7/12/2026

Evidence statusEvidence in progress

Published references1

Trust signal panel

Evidence & safety

Human evidence
n/a
Animal evidence
n/a
Mechanistic
n/a
Safety knowledge
n/a
Editorial confidence
3/5

View in knowledge graph →See this peptide connected to conditions & mechanisms

Evidence Snapshot

Evidence snapshot · 1 verified ref

Overall: 2/5Emerging / preliminary
Human: 2/5Some human clinical evidence
Animal: 0/5None identified
In-vitro: 0/5None identified
Safety: 2/5Partially characterised safety

Scientific identity

Peptide family: Investigational peptide or analogue
Entity class: Research peptide
Alternative names: Modified GRF (1-29)DAC-GRFCJC1295CJC-1295 DACCJC-1295 with DACCJC 1295

Discovery history

CJC-1295 entered research or commercial use through work on its proposed biological, cosmetic or therapeutic activity.

Proposed Mechanisms

GHRH receptor agonism
established
Sustained pulsatile GH release
clinical
Growth hormone-releasing hormone signalling →
supported
Growth hormone axis →
supported

Reported / Studied Uses

Lean mass support
Evidence · limited human
Recovery
Evidence · anecdotal
Muscle Growth / Recovery
Evidence · weak
Growth Hormone Deficiency
Evidence · weak

Human Evidence

Human evidence is absent, limited, early phase or indication-specific.

Animal Evidence

Animal evidence may support biological activity but does not establish clinical efficacy.

Species translation to humans is uncertain.

Safety & Unknowns

research-stagelimited-long-term-datainvestigationalunapproved-product-riskigf-1-elevationcounterfeit-risklong-term-safety-uncertainlimited-human-evidenceno-established-general-use

Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.

Regulatory Status

Country	Status	Notes
World Anti-Doping Agency	Prohibited	Listed under GHRH analogues.
United States	Not FDA-approved	Research chemical status.

Community Observations

No approved community reports yet. Submit one. Aggregate data is observational only.

References

[1]Teichman et al., J Clin Endocrinol Metab 2006 — CJC-1295 pharmacokinetics

Full Disclaimer

This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.

Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.

Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.

↳

Explore further

from the knowledge graph

Mechanisms

Conditions

Related peptides

Sources cited

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
2006 · randomized_placebo_controlled_trial

Advertise here — support independent evidence →